logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
T

Thomas Bieber

ludwig-maximilian university of munich

105H-index
884Paper Count
4.9WCitation Count
Published Papers 412
Publication Date
logo
Reassessing the OX40/OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development program
errJournal of the European Academy of Dermatology and Venereology
IF8
err2026-08-01
err0
errOAAI
errThomas Bieber
errShare
errSave
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis
errJournal of Dermatological Treatment
IF3.9
err2026-05-21
err0
errOAAI
errEmma Guttman-Yassky; Thomas Bieber; Kenji Kabashima; Jan Gutermuth; Stephan Weidinger; Andreas Wollenberg; Irina Lazariciu; Gerardo Encinas; Marina Mikheil; Melissa Watkins
errShare
errSave
Letter to the editor submitted in response to ‘Are potential remittive properties of OX-40 inhibitors something to be excited about?’
errJournal of Dermatological Treatment
IF3.9
err2026-04-16
err0
errOAAI
errAndrew Blauvelt; Thomas Bieber; Stephan Weidinger; Raj Chovatiya; Kassim Rahawi
errShare
errSave
REZPEGALDESLEUKIN, NOVEL TREG-INDUCING THERAPY, DEMONSTRATES EFFICACY IN ATOPIC DERMATITIS AND ASTHMA IN PHASE 2B TRIAL
errAnnals of Allergy, Asthma & Immunology
IF0
err2025-11-05
err0
PREAI
errJ. Corren; P. Lio; J. Silverberg; R. Chovatiya; M. Gooderham; T. Bieber; R. Warren; N. Sadick; J. Treat; S. Gkalpakiotis; A. Reich; S. Chaudhry; Z. Lee; M. Hannaway; D. Yu; Y. Liu; C. Fanton; M. Zhang; W. Waltz; J. Gilbert; S. Charoenthongtrakul; C. Jue; M. Marcondes; B. Kotzin; M. Tagliaferri; J. Zalevsky; D. Rosmarin
errShare
errSave
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis
errCPT: Pharmacometrics & Systems Pharmacology
IF0
err2025-10-01
err0
errOAAI
errGilles Tiraboschi; Kim Papp; Thomas Bieber; Stephan Weidinger; Lisa Beck; Chih-Hung Lee; John T. O'Malley; Karl Yen; Charlotte Bernigaud; David Fabre; Fabrice Hurbin
errShare
errSave
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?
errDermatology and Therapy
IF4.2
err2025-09-23
err0
errOAAI
errEric L. Simpson; Jonathan I. Silverberg; Bob Geng; José-Manuel Carrascosa; Thomas Bieber; Patrick M. Brunner; Delphine Staumont-Sallé; Chao Ji; Pinaki Biswas; Claire Feeney; Irene Hernández-Martín; Francisco José Rebollo Laserna; Herwig Koppensteiner
errShare
errSave
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks
errAmerican Journal of Clinical Dermatology
IF8.8
err2025-09-03
err0
errOAAI
errAlan D. Irvine; Vimal H. Prajapati; Emma Guttman-Yassky; Eric L. Simpson; Kim A. Papp; Andrew Blauvelt; Chia-Yu Chu; H. Chih-ho Hong; Linda F. Stein Gold; Marjolein de Bruin-Weller; Thomas Bieber; Kenji Kabashima; David Rosmarin; Cristina Sancho; Brian M. Calimlim; Ayman Grada; Yang Yang; Xiaoqiang Wu; Gweneth Levy; Eliza M. Raymundo; Henrique D. Teixeira; Jonathan I. Silverberg
errShare
errSave
From Disease Control to Disease Modification: The Atopic Dermatitis Disease Activity Index
errAllergy
IF12
err2025-08-29
err0
errOAAI
errThomas Bieber; Laura Maintz; Ganesh E. Phad; Marie-Charlotte Brüggen
errShare
errSave
Die ADVANCE PN Studie: was können wir daraus lernen?
errjournal der deutschen dermatologischen gesellschaft
IF0
err2025-07-14
err0
PREAI
errThomas Bieber
errShare
errSave
Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
errAdvances in Therapy
IF4
err2025-07-11
err0
errOAAI
errPeter C. Taylor; Thomas Bieber; Rieke Alten; Torsten Witte; James Galloway; Walter Deberdt; Maher Issa; Ewa Haladyj; Inmaculada De La Torre; Susanne Grond; Andreas Wollenberg
errShare
errSave
Langerhans Cell Modulation in Atopic Dermatitis Is TLR2/SOCS1-Dependent and JAK Inhibitor-Sensitive
errAllergy
IF12
err2025-07-09
err0
errOAAI
errYuxuan Deng; Nicole Leib; Sylvia Schnautz; Said Benfadal; Johannes Oldenburg; Thomas Bieber; Nadine Herrmann
errShare
errSave
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
errDERMATOLOGY AND THERAPY
IF4.2
err2025-02-14
err2
errOAAI
errSilverberg, Jonathan I.; Bieber, Thomas; Paller, Amy S.; Beck, Lisa; Kamata, Masahiro; Puig, Luis; Wiseman, Marni; Ezzedine, Khaled; Irvine, Alan D.; Foley, Peter; Del Rosso, James; Gold, Linda Stein; Johansson, Erin; Dossenbach, Martin; Gallo, Gaia; Akmaz, Buelent; Casillas, Marta; Karlsson, Andrei; Curteis, Tristan; Chovatiya, Raj
errShare
errSave
The paradigm shift in drug development for atopic dermatitis: Addressing the variables of the equation leading to disease modification
errANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
IF4.7
err2025-02-01
err3
errOAAI
errBieber, T
errShare
errSave
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)( Sept, 10.1007/s12325-024-02974-y, 2024)
errADVANCES IN THERAPY
IF4
err2024-12-05
err0
errOAAI
errSimpson, Eric; Fernandez-Penas, Pablo; de Bruin-Weller, Marjolein; Lio, Peter A.; Chu, Chia-Yu; Ezzedine, Khaled; Agell, Helena; Casillas, Marta; Ding, Yuxin; Yang, Fan Emily; Pierce, Evangeline; Bieber, Thomas
errShare
errSave
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials
errJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
IF11.8
err2024-12-01
err0
PREAI
errGuttman-Yassky, Emma; Rosmarin, David; de Bruin-Weller, Marjolein; Weidinger, Stephan; Bieber, Thomas; Hong, H. Chih-ho; Elmaraghy, Hany; Atwater, Amber Reck; Pierce, Evangeline; Xu, Chenjia; Agell, Helena; Gil, Esther Garcia; Simpson, Eric
errShare
errSave
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials
errNATURE COMMUNICATIONS
IF15.7
err2024-10-25
err0
errOAAI
errSilverberg, Jonathan I.; Rosmarin, David; Chovatiya, Raj; Bieber, Thomas; Schleicher, Stephen; Beck, Lisa; Gooderham, Melinda; Chaudhry, Sohail; Fanton, Christie; Yu, Danni; Levy, Joshua; Liu, Yi; Miyazaki, Takahiro; Tagliaferri, Mary; Schmitz, Carsten; Nirula, Ajay; Kotzin, Brian; Zalevsky, Jonathan
errShare
errSave
Emerging Biologic Therapies for the Treatment of Atopic Dermatitis
errDRUGS
IF14.4
err2024-10-04
err1
errOAAI
errAlvarenga, Jose Miguel; Bieber, Thomas; Torres, Tiago
errShare
errSave
Cord Blood Serum Levels of IL-31 and CCL17, Cutaneous Markers, and Development of Atopic Dermatitis
errJAMA DERMATOLOGY
IF11
err2024-10-01
err0
PREAI
errDErme, Angelo Massimiliano; Fidanzi, Cristian; Bevilacqua, Matteo; Bieber, Thomas; Tuoni, Cristina; Paolicchi, Aldo; Franzini, Maria; Morganti, Riccardo; Papadia, Francesca; Janowska, Agata; Dini, Valentina; Romanelli, Marco
errShare
errSave
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
errADVANCES IN THERAPY
IF4
err2024-09-09
err0
errOAAI
errSimpson, Eric; Fernandez-Penas, Pablo; de Bruin-Weller, Marjolein; Lio, Peter A.; Chu, Chia-Yu; Ezzedine, Khaled; Agell, Helena; Casillas, Marta; Ding, Yuxin; Yang, Fan Emily; Pierce, Evangeline; Bieber, Thomas
errShare
errSave
Will deciphering the epidermal 'ménage à trois' lead to predictive biomarkers for childhood atopic dermatitis?
errJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
IF8
err2024-08-23
err0
errOAAI
errBieber, Thomas
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
M
Marc Humbert
H-index: 177 · Papers: 2.2K
C
Cezmi A. Akdiş
H-index: 153 · Papers: 1.0K
R
Richard L. Gallo
H-index: 148 · Papers: 884
J
Joachim Heinrich
H-index: 147 · Papers: 1.5K
D
Donald Y.M. Leung
H-index: 135 · Papers: 1.2K
View more